Met160Val polymorphism in the TRMPSS2 gene and risk of prostate cancer in a population-based case-control study

• Published in: The Prostate Vol. 59; no. 4; pp. 357 - 359
• Main Authors: Lubieniecka, Joanna M., Cheteri, Mahesh Keitheri, Stanford, Janet L., Ostrander, Elaine A.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.06.2004
• Subjects: Adult; Case-Control Studies; gene; Genetic Markers; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; mutation; Pedigree; Polymorphism, Genetic; Prostatic Neoplasms - genetics; Risk Factors; Serine Endopeptidases - genetics; serine protease; urologic cancer
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.20005

BACKGROUND Serine proteases play an important role in prostate cancer (PCa) invasion through the degradation of extracellular matrix proteins and interaction with growth modulating factors. The transmembrane serine protease 2 (TMPRSS2) gene encodes a type II transmembrane protein which, due to its cell surface localization, could be a potentially useful predictive marker for PCa. METHODS We screened a population of 24 unrelated individuals for sequence variants in the TMPRSS2 gene, and found a Met160Val change in 33%. We then tested 559 cases and 523 controls from a population‐based case‐control study of middle‐aged men from Washington State. RESULTS Men with the GG genotype and a first‐degree family history of PCa had a significantly higher risk for PCa relative to men without a family history (OR = 2.05; 95% CI = 1.3–3.2). However, the interaction between genotype and family history of PCa was not significant (P = 0.52). CONCLUSIONS Larger, more detailed studies are needed to fully investigate the role of serine proteases in PCa. © 2004 Wiley‐Liss, Inc.